Result: Risk Minimisation Materials for medicines starting with the letter S

Siklos

Nordic Pharma Limited

Siklos Physisican Guide

A guide for prescribers of Siklos

For Healthcare Professionals

Sikos Patient Guide

A guide for patients who are prescribed Siklos

Simponi

Merck Sharp & Dohme Limited

Simponi (Golimumab): Educational Programme Brochure to reduce the risk of adverse events: Healthcare Professionals

As part of the terms of the Marketing Authorisation for Simponi all Healthcare Professionals who are likely to treat patients with golimumab are provided with risk minimisation materials. The Simponi Educational Programme Brochure provides information on 8 key safety aspects of Simponi to reduce the risk of adverse events by ensuring that Healthcare Professionals become aware of the most appropriate patient selection and management and Simponi administration technique. If you require further information about Simponi and hard copies of the material please contact medicalinformationuk@merck.com. If you have any questions or require additional information, please call MSD Medical Information services on 01992 467272.

For Healthcare Professionals

Simponi (Golimumab): Important Safety Information to reduce the risk of adverse events (summary of the Educational Programme Brochure): Healthcare Professional

As part of the terms of the Marketing Authorisation for Simponi all Healthcare Professionals who are likely to treat patients with golimumab are provided with risk minimisation materials. The Important safety information contains a summary of the 8 key safety aspects as detailed in the Simponi educational Programme Brochure. If you require further information about Simponi and hard copies of the material please contact medicalinformationuk@merck.com. If you have any questions or require additional information, please call MSD Medical Information services on 01992 467272.

For Healthcare Professionals

Simponi (Golimumab): Patient Alert Card

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with golimumab.

Skilarence

Almirall Limited

Healthcare Professional Guideline - Important safety information for Skilarence (dimethyl fumarate)

This guideline is intended to inform HCPs about the risk of serious infections, mainly opportunistic infections such as progressive multifocal leukoencephalopathy (PML), associated with the use of Skilarence and to provide guidance on how to minimise and manage this risk through appropriate monitoring of lymphocyte and leukocyte count abnormalities.

For Healthcare Professionals

Sodium valproate

Wockhardt UK Ltd

HCP Guide

Valproate use in female patients

For Healthcare Professionals

Patient Booklet

Valproate use in female patient

Zentiva

Valproate- HCP Booklet – Risks in Female patients

Healthcare professional risk minimisation booklet for Valproate in female patients. For hard copies please contact our medical information department at 08453727101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- HCP Checklist – Risks in Female patients

Checklist for prescribers related to Valproate use in female patients. For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- Letter for Pharmacists – Risks in Female patients

Communication letter to pharmacists explaining risk minimisation materials for managing patients taking Valproate based medicines

For Healthcare Professionals

Valproate- Patient Card – Risks in Female patients

Risk minimisation Patient card for Valproate in female patients. For hard copies please contact our medical information department at 08453727101 or email uk-medicalinformation@sanofi.com .

Valproate- Patient Guide – Risks in Female patients

Patient Guide risk minimisation booklet for Valproate in female patients. For hard copies please contact our medical information department at 08453727101 or email uk-medicalinformation@sanofi.com .

Valproate Pharmacy Poster - Risks in Female patients

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

For Healthcare Professionals

Valproate -Pharmacy shelf barker - Risks in Female patients

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

For Healthcare Professionals

Valproate- Safety card HCP-Risks in Female patients

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate-Letter for Prescriber– Risks in Female patients

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate-Letter for Primary Care HCP – Risks in Female patients

Communication letter to HCP's providing primary care, obstetric or family planning services to female patients taking Valproate containing medicines.

For Healthcare Professionals

Valproate-Letter for Specialists – Risks in Female patients

Communication letter explaining risk minimisation materials for specialists managing patients taking Valproate based medicines.

For Healthcare Professionals

Sofiperla

Actavis UK Ltd

Combined hormonal contraceptives: Checklist for Prescribers

Combined hormonal contraceptives: Checklist for Prescribers

For Healthcare Professionals

Combined hormonal contraceptives: Healthcare Professional Communication

Combined hormonal contraceptives: Healthcare Professional Communication

For Healthcare Professionals

Combined hormonal contraceptives: Important information for women

Combined hormonal contraceptives: Important information for women

Combined hormonal contraceptives: Important information for women about the risk of blood clots

Combined hormonal contraceptives: Important information for women about the risk of blood clots

Soliris

Alexion Pharma UK Ltd

aHUS Parent Information Brochure

This guide is for the parents/legal guardians of young children and Infants. This parent information brochure is a supportive document specifically developed in order to describe the symptoms and steps for early detection and management of meningococcal infections in infants and young children. The primary source of information for patients is within the patient guides.

aHUS Patient and Parent Guide

This guide is for adult patients and parents/legal guardians of adolescent patients suffering from atypical Haemolytic Uraemic Syndrome (aHUS). The guide will provide you with information about the medicine Soliris®, the way in which it will be prescribed and given to you and important safety information of which you should be aware. There is also another guide specifically for parents of young children which your doctor will be able to give you if you wish.

Physician Guide aHUS

Physician’s guide to prescribing Soliris® (eculizumab) for patients with atypical haemolytic uraemic syndrom (aHUS)

For Healthcare Professionals

Physician guide PNH

Physician’s guide to prescribing Soliris® (eculizumab) for patients with paroxysmal nocturnal haemoglobinuria (PNH)

For Healthcare Professionals

PNH Parent Information Brochure

This guide is for parents/legal guardians of young children and Infants. This parent information brochure is a supportive document specifically developed in order to describe the symptoms and steps for early detection and management of meningococcal infections in infants and young children. The primary source of information for patients is within the patient guides.

PNH Patient and Parent Guide

This guide is for adult patients and parents or legal guardians of adolescent patients suffering from Paroxysmal Nocturnal Haemoglobinuria (PNH). The guide will provide you with information about the medicine SOLIRIS®, the way in which it will be prescribed and given to you, and important safety information of which you should be made aware.

Soliris Patient Safety Card

Important Safety Information for Patients Receiving Soliris® Show this card to any doctor involved in your care.

Stelara

Janssen-Cilag Ltd

General Information about Stelara for healthcare professionals.

Information sheet for healthcare professionals using Stelara.

For Healthcare Professionals

Stelara Patient Pack

Stelara Patient Pack - Information for patients who have been prescribed Stelara.

Strensiq

Alexion Pharma UK Ltd

Injection Guide - Parent / Caregivers with Infant Patients

This Injection Guide is for the parents and caregivers of infant patients with paediatric-onset hypophosphatasia who would benefit from long-term enzyme replacement therapy and have been prescribed Strensiq®. The guide gives detailed instructions, with clear diagrams, on how to choose the injection site and how to carry out and record the injection of your infant or child. This guide is designed as a support document to the training given by your healthcare professional. Please contact your healthcare professional if you have any questions.

Self-Injection Guide

This Self-Injection Guide is for patients with paediatric- onset hypophosphatasia who would benefit from long-term enzyme replacement therapy and have been prescribed Strensiq®. The guide gives detailed instructions, with clear diagrams, on how to choose your injection site and how to carry out and record your injection. This guide is designed as a support document to the training given by your healthcare professional. Please contact your healthcare professional if you have any questions.

Strimvelis

GlaxoSmithKline UK

Strimvelis Consent Form

Product consent form for Strimvelis

For Healthcare Professionals

Strimvelis Educational Leaflet for Parents/Carers

An educational leaflet for parents/carers of children who have received gene therapy with Strimvelis

Strimvelis HCP Educational Booklet

Important information for HCPs who provide long-term follow-up for ADA-SCID patients post-treatment with Strimvelis.

For Healthcare Professionals

Strimvelis Patient Alert Card

Alert card for patients who have received Strimvelis

For Healthcare Professionals